Breast Cancer | Specialty

PALB2, BRCA2 Gene Mutations Confer Similar Breast Cancer Risk

August 7th 2014

Women harboring a loss-of-function mutation in the PALB2 gene demonstrated an increased risk of developing breast cancer that was similar to the predisposition seen with mutations in the infamous BRCA gene

Dr. Hurvitz on Treatment Hypotheses for TNBC

August 6th 2014

Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, gives an overview of treatment hypotheses for triple-negative breast cancer (TNBC).

Dr. Halle Moore Discusses Results of the Phase III POEMS Study in Breast Cancer

August 5th 2014

Halle Moore, MD, medical oncologist, Cleveland Clinic, discusses the results of the phase III POEMS study, which was presented at the 2014 ASCO Annual Meeting.

Evolving Therapeutic Landscape in Breast Cancer

August 5th 2014

Case Studies: Treating Metastatic Breast Cancer

August 5th 2014

Clinical Setting for Eribulin in Metastatic Breast Cancer

August 5th 2014

Treatment Strategies in ER-Positive Breast Cancer

August 5th 2014

First-Line ER-Positive MBC Treatments

August 5th 2014

Changing Treatment Landscape in Metastatic Breast Cancer

August 5th 2014

Sorafenib Does Not Improve PFS in Phase III Breast Cancer Study

July 25th 2014

A phase III trial analyzing sorafenib for the treatment of patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival.

Extended Adjuvant Neratinib Improves DFS in Phase III Breast Cancer Study

July 23rd 2014

Extended adjuvant treatment with neratinib (PB272, HKI-272) significantly extended improved disease-free survival (DFS) compared with placebo for patients with HER2-positive breast cancer who received prior adjuvant trastuzumab

Dr. Goldstein on Mechanisms of Resistance to Endocrine Therapy

July 19th 2014

Lori Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, deputy associate director, Clinical Research, Fox Chase Cancer Center, discusses mechanisms of resistance to endocrine therapy.

Dr. Tripathy on Decision-Making for Sequencing Therapies for HER2-Positive MBC

July 18th 2014

Debu Tripathy, MD, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.

Gel, Oral Routes Equivalent for Tamoxifen in DCIS

July 18th 2014

A gel formulation of tamoxifen is equally as effective with fewer side effects when compared with oral tamoxifen in women with ductal carcinoma in situ.

Dr. O'Shaughnessy on Breast Cancer Subtype-Specific Cytotoxic Agents

July 17th 2014

Joyce A. O'Shaughnessy, MD, discusses the evolving area of breast cancer subtype-specific cytotoxic agents.

Giants of Cancer Care Heralded: Ceremony Honors 2nd Annual Giants Class

July 16th 2014

The 2nd Annual Giants of Cancer Careâ„¢ Awards were presented at a ceremony held on May 30 in Chicago. The event recognized 16 oncology heroes whose groundbreaking contributions to the field have improved the lives of patients with cancer.

Risk of Recurrence Low in Small, HER2-Positive Breast Tumors

July 15th 2014

Patients with small, node-negative, HER2-positive breast cancer tumors had a low risk of invasive recurrence after 5 years

T-DM1 Poised to Set New Standard in HER2-Positive Metastatic Breast Cancer

July 14th 2014

The antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) will have an impact on the entire spectrum of care for patients with metastatic HER2-positive breast cancer, resulting in a greater emphasis on patient selection protocols and testing.

Trastuzumab-Associated Cardiac Events Reversible, Outweighed by Benefits

July 14th 2014

Cardiac events associated with trastuzumab are mostly reversible and outweighed by significant extensions in OS and PFS for patients with HER2-positive breast cancer, according to analyses from several clinical trials exploring the drug.

CDK Becomes Hot Target Again: Cell Cycle Inhibitors Compete for Success in Breast Cancer and CLL

July 11th 2014

As gatekeepers of the cell cycle, the cyclin-dependent kinases are often implicated in the progression of cancer and make prime targets for therapy.